Arbutus Biopharma Corp at JMP Securities Life Science Conference Transcript
Hi, good morning. My name is Liisa Bayko, Senior biotech analyst at JMP Securities. I wanted to welcome Arbutus as our first company of the day for our coverage. Arbutus is one of the premier Hep B players and the goal here is to develop and ultimately cures for hepatitis B.
So, we have Mike Sofia and Gaston Picchio from Arbutus joining us. And if there's any questions in the audience, just raise your hand; happy to take your questions as well. But first I think we'll just start off by maybe you can give us an overview of your pipeline and then we'll get into more details.
So yes, Arbutus is a Company focused on developing a cure for hepatitis B. Our strategy focuses around combination strategies to bring forward drugs with multiple mechanisms of action that will ultimately be combined to achieve a durable cure with a finite duration of therapy.
We focused on a number of different areas to achieve that. One is to inhibit viral
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |